| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 19/04/2024 | 22:42 | PR Newswire (US) | Grifols 2023 Annual Report on Form 20-F filed with the SEC | NASDAQ:GRFS | Grifols SA |
| 18/04/2024 | 15:30 | GlobeNewswire Inc. | Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. | NASDAQ:GRFS | Grifols SA |
| 15/04/2024 | 13:06 | IH Market News | Samsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More News | NASDAQ:GRFS | Grifols SA |
| 04/04/2024 | 10:00 | GlobeNewswire Inc. | Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening | NASDAQ:GRFS | Grifols SA |
| 22/03/2024 | 14:07 | IH Market News | FedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest News | NASDAQ:GRFS | Grifols SA |
| 08/03/2024 | 12:19 | IH Market News | CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News | NASDAQ:GRFS | Grifols SA |
| 14/02/2024 | 09:16 | GlobeNewswire Inc. | Grifols announces positive topline phase 3 fibrinogen clinical trial results | NASDAQ:GRFS | Grifols SA |
| 26/01/2024 | 23:14 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRFS | Grifols SA |
| 12/01/2024 | 12:10 | IH Market News | Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More | NASDAQ:GRFS | Grifols SA |
| 10/01/2024 | 12:21 | IH Market News | Wall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and More | NASDAQ:GRFS | Grifols SA |
| 29/12/2023 | 15:59 | Dow Jones News | Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt | NASDAQ:GRFS | Grifols SA |
| 16/11/2023 | 11:00 | PR Newswire (US) | Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients | NASDAQ:GRFS | Grifols SA |
| 15/11/2023 | 14:00 | GlobeNewswire Inc. | Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency | NASDAQ:GRFS | Grifols SA |
| 06/11/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 | NASDAQ:GRFS | Grifols SA |
| 25/10/2023 | 00:30 | GlobeNewswire Inc. | Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD | NASDAQ:GRFS | Grifols SA |
| 19/10/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins | NASDAQ:GRFS | Grifols SA |
| 28/09/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564 | NASDAQ:GRFS | Grifols SA |
| 01/08/2023 | 14:00 | GlobeNewswire Inc. | Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics | NASDAQ:GRFS | Grifols SA |
| 20/07/2023 | 14:15 | GlobeNewswire Inc. | Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients | NASDAQ:GRFS | Grifols SA |
| 18/07/2023 | 14:00 | GlobeNewswire Inc. | Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis | NASDAQ:GRFS | Grifols SA |
| 13/07/2023 | 14:00 | GlobeNewswire Inc. | Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency | NASDAQ:GRFS | Grifols SA |
| 20/06/2023 | 13:13 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GRFS | Grifols SA |
| 15/06/2023 | 01:34 | Dow Jones News | ADRs End Higher, Grifols, Victrex Trade Actively | NASDAQ:GRFS | Grifols SA |
| 14/06/2023 | 12:44 | Dow Jones News | Grifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 Billion | NASDAQ:GRFS | Grifols SA |
| 11/05/2023 | 14:30 | GlobeNewswire Inc. | Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD | NASDAQ:GRFS | Grifols SA |
| 10/05/2023 | 01:31 | Dow Jones News | ADRs End Mostly Lower, Natura & Co. and Grifols Trade Actively | NASDAQ:GRFS | Grifols SA |
| 18/04/2023 | 16:30 | PR Newswire (US) | Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 | NASDAQ:GRFS | Grifols SA |
| 18/04/2023 | 15:27 | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:GRFS | Grifols SA |
| 06/03/2023 | 13:00 | PR Newswire (US) | Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease | NASDAQ:GRFS | Grifols SA |
| 05/12/2022 | 13:05 | TipRanks | Grifols SA (GRFS) Gets a Hold from J.P. Morgan | NASDAQ:GRFS | Grifols SA |